Market News

Global Herpes Simplex Virus Treatment Market: Key Developments

In January 2023, Molbio Diagnostics launched the Truenat HSV 1/2 for testing the herpes simplex virus. The test is approved by CDSCO and can provide sample-to-test results in an hour. The real-time PCR test works on the existing Truelab infrastructure and doesn' t require additional setup and equipment to run the test, making it possible to test at resource-limited settings.

In October 2021, United BioPharma collaborated with Shanghai Public Health Clinical Centre and Cheng Kung University' s Department of Microbiology and Immunology to investigate the efficacy of UB-621, a best-in-class long-acting medication for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2).

In July 2021, Rational Vaccines received the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) Innovation Passport for RVx201, a therapeutic vaccine developed for genital herpes resulting from the herpes simplex type 2 (HSV-2) virus.

In May 2020, Shionogi & Co. and Genocea Biosciences Inc. teamed up to develop herpes simplex vaccine. Under a material transfer agreement, Shionogi will evaluate certain herpes simplex virus type 2, antigens from Genocea' s GEN-003 program.

Global Herpes Simplex Virus Treatment Market: Key Companies Insights